膀胱癌治疗和诊断市场 - 全球产业规模、份额、趋势、机会和预测，按治疗、诊断、癌症类型、地区和竞争细分，2020-2030 年预测

2024 年全球膀胱癌治疗和诊断市场价值为 4.5022 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 7.50%。当膀胱内壁的健康细胞（最常见的是尿路上皮细胞）发生不受控制的变化和扩张，形成称为肿瘤的肿块时，就会发展为膀胱癌。肾盂、输尿管和尿道均覆盖尿路上皮细胞。另一种尿路上皮癌称为上尿路上皮癌，是起源于肾盂和输尿管的癌症。其治疗方法通常与本指南中讨论的膀胱癌治疗方法类似。肿瘤可能是良性的，也可能是恶性的。恶性是指癌性肿瘤具有发展并转移到身体不同部位的能力。如果肿瘤是良性的，它可以增大但不会扩散。良性膀胱肿瘤很少发生。全球膀胱癌发生率不断上升，尤其是在老年人口中，是一个重要驱动因素。膀胱癌病例数量的不断增加导致了患者数量的增加，从而推动了对诊断和治疗的需求。

诊断技术的不断改进，包括增强成像技术、尿液生物标记测试和基因分析，提高了膀胱癌的早期检测和诊断能力，从而增加了对诊断的需求。免疫疗法（例如检查点抑制剂）和标靶疗法等新型治疗方法的发展扩大了膀胱癌患者的治疗选择并改善了其治疗效果。这些创新推动了市场成长。正在进行的临床试验和研究计划旨在探索新的治疗方法、联合疗法和个人化医疗方法，为市场扩张创造了机会。全球人口老化使人们更容易罹患膀胱癌。随着老年人口的增长，膀胱癌的盛行率预计会增加，导致对治疗和诊断的需求增加。

主要市场驱动因素

增加创新疗法

主要市场挑战

治疗费用高昂

主要市场趋势

微创手术技术

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：全球膀胱癌治疗与诊断市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依治疗方法（化疗、免疫疗法、其他疗法）
  • 透过诊断（膀胱镜检查、膀胱超音波检查、尿液分析、其他诊断）
  • 依癌症类型（膀胱移行细胞癌、膀胱鳞状细胞癌、其他癌症类型）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：亚太地区膀胱癌治疗与诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 7 章：欧洲膀胱癌治疗与诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 8 章：北美膀胱癌治疗与诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 9 章：南美洲膀胱癌治疗与诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲膀胱癌治疗和诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球膀胱癌治疗与诊断市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章： 大环境分析

第 16 章：竞争格局

• Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Novartis International AG
• Pfizer Inc.
• Abbott Inc.
• Endo Pharmaceuticals Inc.
• Johnson & Johnson (Janssen Pharmaceutical)
• Merck & Co. Inc
• Astellas Pharma Inc.

第 17 章：策略建议

第18章调查会社について・免责事项

Global Bladder Cancer Therapeutics and Diagnostics Market was valued at USD 450.22 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.50% through 2030. When healthy cells in the bladder lining most frequently urothelial cells change and expand uncontrollably, forming a mass known as a tumor, bladder cancer develops. The renal pelvis, ureters, and urethra are all lined with urothelial cells. Another form of urothelial cancer, known as upper tract urothelial carcinoma, is cancer that originates in the renal pelvis and ureters. It is often treated in a manner like that discussed in this guidance for bladder cancer. A tumor may be benign or malignant. Malignant refers to the ability of a cancerous tumor to develop and metastasize to different body regions. If a tumor is benign, it can enlarge but won't spread. Rarely do benign bladder tumors occur. A rising global incidence of bladder cancer, especially in aging populations, has been a significant driver. The growing number of bladder cancer cases creates a larger patient pool, driving demand for diagnostics and therapeutics.

Continuous improvements in diagnostic techniques, including enhanced imaging technologies, urine-based biomarker tests, and genetic profiling, have improved early detection and diagnosis of bladder cancer, thereby increasing the demand for diagnostics. The development of novel therapeutic approaches, such as immunotherapies (e.g., checkpoint inhibitors) and targeted therapies, has expanded treatment options and improved outcomes for bladder cancer patients. These innovations drive market growth. Ongoing clinical trials and research initiatives to explore new treatments, combination therapies, and personalized medicine approaches create opportunities for market expansion. The aging global population is more susceptible to bladder cancer. As the elderly population grows, the prevalence of bladder cancer is expected to increase, leading to higher demand for therapeutics and diagnostics.

Key Market Drivers

Increasing Innovative Therapies

Innovative therapies in cancer therapeutics and diagnostics have transformed the way cancer is diagnosed and treated. These groundbreaking approaches offer new hope for patients and have the potential to improve outcomes while reducing side effects. For instance, according to Cancer Research UK, approximately 90% of bladder cancers in the UK are urothelial cancers, also called transitional cell cancers. Immunotherapy harnesses the body's immune system to target and destroy cancer cells. Immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines are among the most promising approaches. These therapies have shown remarkable results in various cancers, including melanoma, lung cancer, and leukemia. Precision medicine, also known as personalized medicine, tailors cancer treatment based on a patient's genetic, genomic, and molecular profile. Targeted therapies, such as tyrosine kinase inhibitors and PARP inhibitors, are designed to specifically target the genetic mutations or abnormalities driving a patient's cancer. Gene therapy involves the introduction or modification of genes to treat or prevent diseases, including cancer. CAR-T cell therapy is a prime example, where a patient's T cells are genetically engineered to target cancer cells with precision. Cancer vaccines stimulate the immune system to recognize and attack cancer cells. Therapeutic cancer vaccines aim to treat existing cancer, while preventive vaccines, like the HPV vaccine, prevent certain cancers from developing. Liquid biopsies involve analyzing blood, urine, or other bodily fluids to detect cancer-specific biomarkers, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). These tests are minimally invasive and can provide insights into a patient's cancer status, treatment response, and minimal residual disease. Innovations in radiation therapy, such as intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy, allow for highly targeted radiation delivery, minimizing damage to healthy tissue.

Key Market Challenges

High Treatment Costs

The financial burden associated with bladder cancer diagnosis and treatment affects not only patients but also healthcare systems and society. The diagnostic process for bladder cancer often includes multiple procedures, such as cystoscopy, imaging (CT scans, MRI), urine tests, and potentially invasive biopsies. These diagnostic tests and procedures can accumulate substantial costs. Bladder cancer treatment options vary depending on the stage and type of cancer. Treatments may include surgery, chemotherapy, radiation therapy, immunotherapy, or a combination of these approaches. Each of these treatment modalities carries its own cost implications. Surgical procedures for bladder cancer, whether open or minimally invasive, can be expensive. Costs include surgeon fees, operating room expenses, anesthesia, and hospitalization. Immunotherapy and targeted therapies, while offering promising outcomes, can be expensive due to the high cost of drug development and administration. Some of these treatments are administered over an extended period. External beam radiation therapy and brachytherapy are common treatments for bladder cancer. The cost of radiation therapy includes the use of specialized equipment and personnel. The cost of chemotherapy drugs, as well as the monitoring and management of side effects, can be a significant financial burden on patients and healthcare systems. Bladder cancer patients often require long-term surveillance and monitoring for recurrence. This includes regular check-ups, imaging, and urine tests, which can add to the overall cost of care.

Key Market Trends

Minimally Invasive Surgical Techniques

Minimally invasive surgical techniques, such as laparoscopic and robotic-assisted surgery, often result in smaller incisions, less pain, and faster recovery times compared to open surgery. This leads to improved post-operative outcomes and a better quality of life for bladder cancer patients. Minimally invasive procedures typically require shorter hospital stays, reducing healthcare costs and freeing up hospital resources for other patients. Robotic-assisted surgery allows for precise removal of bladder tumors while preserving healthy tissue. This is especially important for patients with non-muscle-invasive bladder cancer (NMIBC) where tumor recurrence is a concern. Smaller incisions and reduced tissue trauma lower the risk of surgical site infections, which is a significant concern in open surgeries. Patients who undergo minimally invasive procedures often experience quicker recoveries, enabling them to return to their daily activities and work sooner. Minimally invasive techniques are associated with less pain and discomfort during the post-operative period, reducing the need for heavy pain medications. Smaller incisions result in less visible scarring, which can be particularly important for patients' body image and self-esteem. Laparoscopic and robotic systems provide surgeons with enhanced visualization of the surgical site, allowing for more precise tumor removal and reduced damage to healthy tissue.

Key Market Players

• Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Novartis International AG
• Pfizer Inc.
• Abbott Inc.
• Endo Pharmaceuticals Inc.
• Johnson & Johnson (Janssen Pharmaceutical)
• Merck & Co. Inc
• Astellas Pharma Inc.

Report Scope:

In this report, the Global Bladder Cancer Therapeutics and Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bladder Cancer Therapeutics and Diagnostics Market, By Therapeutics:

• Chemotherapy
• Immunotherapy
• Other Therapeutics

Bladder Cancer Therapeutics and Diagnostics Market, By Diagnostics:

• Cystoscopy
• Bladder Ultrasound
• Urinalysis
• Other Diagnostics

Bladder Cancer Therapeutics and Diagnostics Market, By Cancer Type:

• Transitional Cell Bladder Cancer
• Squamous Cell Bladder Cancer
• Other Cancer Types

Bladder Cancer Therapeutics and Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bladder Cancer Therapeutics and Diagnostics Market.

Available Customizations:

Global Bladder Cancer Therapeutics and Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutics (Chemotherapy, Immunotherapy, Other Therapeutics)
  • 5.2.2. By Diagnostics (Cystoscopy, Bladder Ultrasound, Urinalysis, Other Diagnostics)
  • 5.2.3. By Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutics
  • 6.2.2. By Diagnostics
  • 6.2.3. By Cancer Type
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutics
      • 6.3.1.2.2. By Diagnostics
      • 6.3.1.2.3. By Cancer Type
  • 6.3.2. India Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutics
      • 6.3.2.2.2. By Diagnostics
      • 6.3.2.2.3. By Cancer Type
  • 6.3.3. Australia Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutics
      • 6.3.3.2.2. By Diagnostics
      • 6.3.3.2.3. By Cancer Type
  • 6.3.4. Japan Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Therapeutics
      • 6.3.4.2.2. By Diagnostics
      • 6.3.4.2.3. By Cancer Type
  • 6.3.5. South Korea Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Therapeutics
      • 6.3.5.2.2. By Diagnostics
      • 6.3.5.2.3. By Cancer Type

7. Europe Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutics
  • 7.2.2. By Diagnostics
  • 7.2.3. By Cancer Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutics
      • 7.3.1.2.2. By Diagnostics
      • 7.3.1.2.3. By Cancer Type
  • 7.3.2. Germany Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutics
      • 7.3.2.2.2. By Diagnostics
      • 7.3.2.2.3. By Cancer Type
  • 7.3.3. Spain Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutics
      • 7.3.3.2.2. By Diagnostics
      • 7.3.3.2.3. By Cancer Type
  • 7.3.4. Italy Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutics
      • 7.3.4.2.2. By Diagnostics
      • 7.3.4.2.3. By Cancer Type
  • 7.3.5. United Kingdom Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutics
      • 7.3.5.2.2. By Diagnostics
      • 7.3.5.2.3. By Cancer Type

8. North America Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutics
  • 8.2.2. By Diagnostics
  • 8.2.3. By Cancer Type
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutics
      • 8.3.1.2.2. By Diagnostics
      • 8.3.1.2.3. By Cancer Type
  • 8.3.2. Mexico Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutics
      • 8.3.2.2.2. By Diagnostics
      • 8.3.2.2.3. By Cancer Type
  • 8.3.3. Canada Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutics
      • 8.3.3.2.2. By Diagnostics
      • 8.3.3.2.3. By Cancer Type

9. South America Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutics
  • 9.2.2. By Diagnostics
  • 9.2.3. By Cancer Type
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutics
      • 9.3.1.2.2. By Diagnostics
      • 9.3.1.2.3. By Cancer Type
  • 9.3.2. Argentina Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutics
      • 9.3.2.2.2. By Diagnostics
      • 9.3.2.2.3. By Cancer Type
  • 9.3.3. Colombia Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application

10. Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutics
  • 10.2.2. By Diagnostics
  • 10.2.3. By Cancer Type
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutics
      • 10.3.1.2.2. By Diagnostics
      • 10.3.1.2.3. By Cancer Type
  • 10.3.2. Saudi Arabia Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutics
      • 10.3.2.2.2. By Diagnostics
      • 10.3.2.2.3. By Cancer Type
  • 10.3.3. UAE Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutics
      • 10.3.3.2.2. By Diagnostics
      • 10.3.3.2.3. By Cancer Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Bladder Cancer Therapeutics and Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Bristol-Myers Squibb Company
• 16.3. Eli Lilly and Company
• 16.4. F. Hoffmann-La Roche Ltd
• 16.5. GlaxoSmithKline PLC
• 16.6. Novartis International AG
• 16.7. Pfizer Inc.
• 16.8. Abbott Inc.
• 16.9. Endo Pharmaceuticals Inc.
• 16.10.Johnson & Johnson (Janssen Pharmaceutical)
• 16.11. Merck & Co. Inc
• 16.12. Astellas Pharma Inc.

17. Strategic Recommendations

18. About Us & Disclaimer